171 related articles for article (PubMed ID: 18221677)
1. [New therapeutic options in protracted HIV-infected patients with virological failure].
Moreno Cuerda VJ; Rubio García R; Morales Conejo M
Med Clin (Barc); 2008 Jan; 130(2):66-70. PubMed ID: 18221677
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
3. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Arribas JR
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
[TBL] [Abstract][Full Text] [Related]
5. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Edmunds-Ogbuokiri T
HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
[No Abstract] [Full Text] [Related]
6. Use of darunavir and enfuvirtide in a pregnant woman.
Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
[TBL] [Abstract][Full Text] [Related]
7. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
9. HIV entry and fusion inhibitors.
Chantry D
Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
[TBL] [Abstract][Full Text] [Related]
10. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
11. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
[TBL] [Abstract][Full Text] [Related]
12. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
13. An update and review of antiretroviral therapy.
Piacenti FJ
Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
[TBL] [Abstract][Full Text] [Related]
14. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
Palladino C; Briz V; González-Tomé MI; León Leal JA; Navarro ML; de José MI; Ramos JT; Muñoz-Fernández MA
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):301-5. PubMed ID: 20334565
[TBL] [Abstract][Full Text] [Related]
15. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
16. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation.
Sozio F; Polilli E; D'Annunzio M; Falconi L; Di Masi F; Tontodonati M; Cosentino L; Consorte A; Di Giammartino D; Parruti G
Infez Med; 2009 Dec; 17(4):228-35. PubMed ID: 20046103
[TBL] [Abstract][Full Text] [Related]
18. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
[TBL] [Abstract][Full Text] [Related]
19. [Position of darunavir in antiretroviral therapy].
Clotet B
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():61-2. PubMed ID: 19195461
[No Abstract] [Full Text] [Related]
20. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
[Next] [New Search]
